Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MacroGenics Inc MGNX

Healthcare Biotechnology
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor... see more

Recent & Breaking News (NDAQ:MGNX)

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against MacroGenics, Inc.

Accesswire September 5, 2024

Investors who lost money on MacroGenics, Inc.(MGNX) should contact The Gross Law Firm about pending Class Action - MGNX

PR Newswire September 5, 2024

MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman

Newsfile September 4, 2024

Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX

Accesswire September 4, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics

Accesswire September 4, 2024

MacroGenics, Inc. Class Action: Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX

Accesswire September 4, 2024

Shareholders that lost money on MacroGenics, Inc.(MGNX) should contact Levi & Korsinsky about pending Class Action - MGNX

Accesswire September 3, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit - MGNX

Accesswire September 3, 2024

MGNX Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Shareholders of Securities Fraud Class Action Lawsuit Deadline

Accesswire September 3, 2024

ROSEN, A LONGSTANDING LAW FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MGNX

Newsfile September 3, 2024

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics

Newsfile September 3, 2024

MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire September 3, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX

PR Newswire September 3, 2024

Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors - Contact Levi & Korsinsky

Accesswire September 3, 2024

MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman

Accesswire September 3, 2024

MacroGenics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX

Accesswire September 3, 2024

The Schall Law Firm Wants Stockholders In MacroGenics Inc. To Participate In A Case For Securities Fraud

Accesswire September 3, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. Lawsuit - MGNX

Accesswire September 3, 2024

MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

PR Newswire September 3, 2024

Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX

PR Newswire September 3, 2024